Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks

ArriVent BioPharma, an early adopter of the China licensing model, reported that its lead lung cancer drug failed a Phase 3 trial. Firmonertinib, an EGFR inhibitor, was first approved for lung ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at endpoints.news →

More in Health & Medicine

More from Tuesday 6 October →